Key Figures1

kEUR

H1 2022

H1 2021

Change

 

 

 

 

Revenue

133,656

135,136

-1.1%

Custom Projects

72,613

76,207

-4.7%

Contract Manufacturing

48,398

45,765

5.8%

Generics & Cosmetics

12,645

13,164

-3.9%

EBITDA

26,706

39,889

-33.1%

Adjusted 2 EBITDA

26,706

43,240

-38.2%

Adjusted 2 EBITDA in % of revenue

20.0%

32.0%

-12.0 ppts

Operating result (EBIT)

15,482

30,803

-49.7%

Operating result (EBIT) in % of revenue

11.6%

22.8%

-11.2 ppts

Result for the period

10,247

24,623

-58.4%

Result for the period in % of revenue

7.7%

18.2%

-10.6 ppts

Earnings per share (EUR), basic

0.31

0.79

-60.9%

Return on net operating assets (RONOA)

14.3%

25.6%

-11.4 ppts

Cash and cash equivalents (end of period)

66,436

187,362

-64.5%

Net cash flow from operating activities

-7,659

41,048

-118.7%

Capital expenditures

37,926

24,989

51.8%

Capital expenditures in % of revenue

28.4%

18.5%

9.9 ppts

Total assets (end of period)

579,253

571,950

1.3%

Equity ratio (end of period)

73.8%

67.4%

6.3 ppts

Employees (# of FTEs, average)

1,156

1,026

12.7%

1 This table and report include references to operational indicators and alternative financial performance measures (APM) that are not defined or specified by IFRS. These APM should be regarded as complementary information to and not as substitutes of the Group’s consolidated financial results based on IFRS. For the definitions of the main operational indicators and APM used, including related abbreviations, as well as for selected reconciliations to IFRS, please refer to the section “Definitions and reconciliations” of this report.

2 For H1 2022, no EBITDA adjustments were recognized. Adjusted EBITDA for H1 2021 excludes one-off IPO costs of EUR 5.7 million, partly offset by US government loans of EUR 2.4 million waived in context of the coronavirus pandemic.